Shots: NICE has recommended Ilumetri (tildrakizumab) as a cost-effective option for the treatment of adults patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy following its assessment submission […]readmore
Tags : ILUMETRI
Regulatory
Almirall’s Ilumetri (tildrakizumab) Receives NICE’s Provisional Approval for Moderate-To-Severe Plaque
Shots: The approval is based on P-III reSURFACE 1 & reSURFACE 2 studies assessing Ilumetri (tildrakizumab) in 1,800 patients with moderate-to-severe plaque psoriasis across 200 sites WW reSURFACE 1 & […]readmore
Shots: Ilumetri’s (tildrakizumab) approval is based on the positive results from reSURFACE 1 and 2 P-III clinical trial, testing its safety and efficacy in >200 clinical sites worldwide reSURFACE 1 […]readmore